Susquehanna International Group
CTNM

Susquehanna International Group’s Contineum Therapeutics CTNM Stock Holding History

Susquehanna International Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Buy
11,300
+1,100
+11% +$14.8K ﹤0.01% 12020
2025
Q4 		$117K Buy
+10,200
New +$116K ﹤0.01% 11365

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's CTNM Position: Q1 2026 in Review

Susquehanna International Group increased its Contineum Therapeutics (CTNM) stake by 40% in Q1 2026, buying an estimated $1.42M and bringing the position to 371,636 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #4284.

Susquehanna International Group first reported a position in CTNM in Q1 2025 and has held it in 5 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Susquehanna International Group held 371,636 shares of Contineum Therapeutics worth $4.85M as of Q1 2026.
  • Susquehanna International Group bought 105,875 Contineum Therapeutics shares in Q1 2026, an estimated $1.42M.
  • Contineum Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4284 holding.
  • Susquehanna International Group first reported a position in Contineum Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.